Evidence Hub

Scintigraphy-Positive Light-Chain Cardiac Amyloidosis

Ezegwu O, Oredipe O, Malhotra S

Journal of nuclear medicine technology, 2026

Abstract

We report the cases of 3 patients with biopsy-proven light-chain cardiac amyloidosis (AL-CA) presenting with varying clinical manifestations and abnormal findings on Tc-based bone-avid scintigraphy, illustrating the diagnostic challenges of distinguishing AL-CA from transthyretin-related CA. All patients demonstrated typical electrocardiographic and echocardiographic features of CA, including low voltage and apical-sparing strain pattern. Despite abnormal scintigraphy suggestive of transthyretin-related CA, concurrent abnormal light-chain assays raised diagnostic uncertainty. Endomyocardial biopsy with mass spectrometry confirmed AL-CA in all cases. These cases emphasize the heterogeneous presentation of CA and the essential role of light-chain assays, regardless of the presence of myocardial uptake pattern on scintigraphy.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free